Cargando…

Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles

Drug Target Commons (DTC) is a web platform (database with user interface) for community-driven bioactivity data integration and standardization for comprehensive mapping, reuse and analysis of compound–target interaction profiles. End users can search, upload, edit, annotate and export expert-curat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanoli, ZiaurRehman, Alam, Zaid, Vähä-Koskela, Markus, Ravikumar, Balaguru, Malyutina, Alina, Jaiswal, Alok, Tang, Jing, Wennerberg, Krister, Aittokallio, Tero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146131/ https://www.ncbi.nlm.nih.gov/pubmed/30219839 http://dx.doi.org/10.1093/database/bay083

Ejemplares similares

Exploration of databases and methods supporting drug repurposing: a comprehensive survey
por: Tanoli, Ziaurrehman, et al.
Publicado: (2020)

Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions
por: Tang, Jing, et al.
Publicado: (2018)

Using BERT to identify drug-target interactions from whole PubMed
por: Aldahdooh, Jehad, et al.
Publicado: (2022)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors
por: Cichonska, Anna, et al.
Publicado: (2017)

C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments through compound-specific bioactivity dendrograms
por: Ravikumar, Balaguru, et al.
Publicado: (2017)

Multi‐modal meta‐analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor
por: Jaiswal, Alok, et al.
Publicado: (2021)

DrugRepo: a novel approach to repurposing drugs based on chemical and genomic features
por: Wang, Yinyin, et al.
Publicado: (2022)

TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples
por: He, Liye, et al.
Publicado: (2015)

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening
por: Gupta, Abhishekh, et al.
Publicado: (2020)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experiments
por: Tanoli, Ziaurrehman, et al.
Publicado: (2021)

Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments
por: Tanoli, Ziaurrehman, et al.
Publicado: (2021)

Crowdsourced mapping of unexplored target space of kinase inhibitors
por: Cichońska, Anna, et al.
Publicado: (2021)

SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets
por: Zheng, Shuyu, et al.
Publicado: (2022)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach
por: Ali, Mehreen, et al.
Publicado: (2018)

DrugComb: an integrative cancer drug combination data portal
por: Zagidullin, Bulat, et al.
Publicado: (2019)

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
por: Jaiswal, Alok, et al.
Publicado: (2017)

Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression
por: Ammad-ud-din, Muhammad, et al.
Publicado: (2017)

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways
por: Tang, Jing, et al.
Publicado: (2013)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

MediSyn: uncertainty-aware visualization of multiple biomedical datasets to support drug treatment selection
por: He, Chen, et al.
Publicado: (2017)

Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells
por: Denisova, Oxana V., et al.
Publicado: (2022)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

Target-specific compound selectivity for multi-target drug discovery and repurposing
por: Wang, Tianduanyi, et al.
Publicado: (2022)

Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring
por: Mäkinen, Lotta, et al.
Publicado: (2022)

Improved detection of differentially represented DNA barcodes for high‐throughput clonal phenomics
por: Akimov, Yevhen, et al.
Publicado: (2020)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

Toward more realistic drug–target interaction predictions
por: Pahikkala, Tapio, et al.
Publicado: (2015)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival
por: Elmadani, Manar, et al.
Publicado: (2019)

Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer
por: Wang, Tianduanyi, et al.
Publicado: (2020)

SynergyFinder 2.0: visual analytics of multi-drug combination synergies
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer
por: Kangaspeska, Sara, et al.
Publicado: (2016)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

Machine learning and feature selection for drug response prediction in precision oncology applications
por: Ali, Mehreen, et al.
Publicado: (2018)

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
por: Tang, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dmievmc9q8j38jbh144p54p7kk